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Abstract
Background:  The acquisition of drug resistance is a major reason for poor outcome of
neuroblastoma. Protein kinase C (PKC) has been suggested to influence drug resistance in cancer
cells. The aim of this study was to elucidate whether inhibition of PKCβ isoforms influences drug-
resistance of neuroblastoma cells.
Methods: The effect of the PKCβ inhibitor LY379196 on the growth-suppressing effects of
different chemotherapeutics on neuroblastoma cells was analyzed with MTT assays. The effect of
LY379196 on the accumulation of [3H]vincristine was also investigated
Results: The PKCβ inhibitor LY379196 suppressed the growth of three neuroblastoma cell lines.
LY379196 also augmented the growth-suppressive effect of doxorubicin, etoposide, paclitaxel, and
vincristine, but not of carboplatin. The effect was most marked for vincristine and for the cell-line
(SK-N-BE(2)) that was least sensitive to vincristine. No effect was observed on the non-resistant
IMR-32 cells. Two other PKC inhibitors, Gö6976 and GF109203X, also enhanced the vincristine
effect. The PKC inhibitors caused an increased accumulation of [3H]vincristine in SK-N-BE(2) cells.
Conclusions:  This indicates that inhibition of PKCβ could attenuate multidrug resistance in
neuroblastoma cells by augmenting the levels of natural product anticancer drugs in resistant cells.
Background
Neuroblastoma is a childhood tumor originating from the
peripheral sympathetic nervous system. It is characterized
of two different patterns of disease progress. One, fre-
quently occurring in very young children and without am-
plification of the MYCN  gene, is often associated with
good prognosis and sometimes even with spontaneous re-
gression. The other group of tumors, however, often in-
volving slightly older children and with MYCN
amplification is associated with poor prognosis [1]. A
common feature of highly malignant neuroblastoma is
the acquisition of multidrug resistance [2].
Protein kinase C (PKC) constitutes a family of closely re-
lated protein serine/threonine kinase which are sub-
grouped into classical (PKCα, βI, βII, and γ), novel (PKCδ,
ε, η, and θ), and atypical (PKCι and ζ) isoforms. The basis
for this classification is different domain structure and ac-
tivator requirements of the isoforms [3]. The members of
the PKC family are involved in the regulation of numer-
ous cell processes including proliferation, apoptosis, and
differentiation. It is likely that each isoform has a specific
role in a given cell.
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We have shown that neuroblastoma cells express PKCα,
βI, and βII of the classical isoforms and PKCδ and ε of the
novel isoforms [4,5]. Of these isoforms PKCε is a positive
regulator of neurite outgrowth during differentiation of
these cells [6,7] whereas PKCβI seems to have a positive
role for neuroblastoma cell proliferation [5]. The latter
study also indicated that inhibition of PKCβ could poten-
tiate the growth suppressive effect of microtubule-inter-
acting anticancer drugs.
The aim of this study was to investigate whether inhibi-
tion of PKCβ isoforms could be utilized to potentiate the
effects of chemotherapeutic drugs on neuroblastoma
cells. For that purpose three cell lines, one without MYCN
amplification (SH-SY5Y), and two MYCN-amplified
(IMR-32 and SK-N-BE(2)), were screened for the combi-
natorial effects of the PKCβ inhibitor and several chemo-
therapeutic drugs. One of these cell lines, SK-N-BE(2), has
been shown to exhibit resistance to a broad range of anti-
cancer compounds.
We found that the specific PKCβ inhibitor LY379196 sup-
pressed the growth of all three neuroblastoma cell lines
studied and that it potentiated the growth-suppressive ef-
fect of all investigated chemotherapeutics, except carbopl-
atin, on the drug-resistant SK-N-BE(2) cell line.
Furthermore, LY379196 potentiated the accumulation of
[3H]vincristine in the SK-N-BE(2) cells suggesting that an
effect on the elimination of the chemotherapeutic drugs is
the mechanism whereby LY379196 influences the effect
on cell growth.
Methods
Cell lines
IMR-32, SH-SY5Y, and SK-N-BE(2) neuroblastoma cells
were maintained in Eagle's minimal essential medium
supplemented with 10% FCS, 100 IU/ml penicillin and
100  µg/ml streptomycin (all cell culture reagents were
from Gibco).
Cell viability analysis
Cells were seeded at a density of 5000 cells per well in 96
well plates and cultured for three (SK-N-BE(2)) or four
(IMR-32 and SH-SY5Y) days. Drugs had been added to the
wells prior to addition of cells. LY379196 (kindly provid-
ed by Eli Lilly Research Laboratories), GF109203X and
Gö6976 (Calbiochem), and etoposide and paclitaxel (Sig-
ma) were solubilized in DMSO. Vincristine (Sigma) and
carboplatin and doxorubicin (ICN) were solubilized in
water. The amount of viable cells in the wells were ana-
lyzed with an MTT assay (Promega) according to the sup-
plier's protocol. To calculate the drug concentration that
gives 50% viable cells compared to control conditions a
non-linear curve fit, y = A2 - (A1 - A2)/(1 + B/x), was per-
formed on the experimental data. With the parameter val-
ues obtained from the curve fit, we calculated the
anticancer drug concentration that reduced the amount of
viable cells to 50%. This was done in two ways to both
show the effect of LY379196 on the potency of the chem-
otherapeutic drug and to illustrate the total effect of the
combination of LY379196 and the chemotherapeutic
drug on neuroblastoma cell growth. In the first case, the
amount of cells in the absence of chemotherapeutic drug
but in the presence of the particular LY379196 concentra-
tion was set to 100%, and the concentration of anticancer
drug that gave 50% was calculated. In the second case, the
amount of cells in the absence of both PKC inhibitor and
chemotherapeutic drug was set to 100%. For each
LY379196 concentration, the concentration of chemo-
therapeutic drug that suppressed the amount of cells to
50% was thereafter calculated.
Accumulation of [3H]vincristine
SK-N-BE(2) cells were seeded at a density of 100,000 cells/
well in a 24-well plate. The next day PKC inhibitors were
added at indicated concentrations and 15 min later
[3H]vincristine (final concentration 1 µM, 0.25 Ci/mmol
[Amersham Pharmacia Biotech]) was added. After 2 h the
plate was put on ice and cells were washed three times
with PBS. Cells were lysed in 10 mM NaH2PO4, pH 7.4,
1% Triton X-100, and 0.2% SDS and thereafter transferred
to vials for scintillation counting.
Results
In a previous study we found that inhibition of PKCβ with
LY379196 suppresses the proliferation and growth of SK-
N-BE(2) cells [5]. In order to examine whether this is a cell
line-specific effect, or if it is more general in terms of neu-
roblastoma cells, three neuroblastoma cell lines – IMR-32,
SH-SY5Y, and SK-N-BE(2) – were cultured in the presence
of increasing concentrations of LY379196 (Figure 1). This
showed that all cell lines were sensitive to LY379196. At a
concentration of 300 nM, LY379196 suppressed the
number of viable cells with 16–24% for the three cell
lines, which indicates that a PKCβ isoform has a positive
effect on neuroblastoma cell growth.
To elucidate a putative synergistic effect of the PKCβ in-
hibitor and different anticancer drugs used for neuroblas-
toma therapy the three cell lines were cultured in the
presence of increasing concentrations of doxorubicin,
etoposide, paclitaxel, vincristine, or carboplatin together
with different concentrations of LY379196 (Figure 2, Ta-
ble 1). The cell lines displayed different sensitivity to the
anticancer drugs. IMR-32 was consistently the most sensi-
tive to all drugs investigated. SH-SY5Y and IMR-32 were
equally sensitive to the topoisomerase inhibitors doxoru-
bicin and etoposide whereas SH-SY5Y cells were three- to
four-fold less sensitive to the microtubule interacting
agents paclitaxel and vincristine and to the DNABMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/10
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intercalator carboplatin. SK-N-BE(2) was the most resist-
ant cell line being more than fifty-fold more resistant to
doxorubicin, etoposide and carboplatin than the other
cell lines. SK-N-BE(2) cells also displayed a substantially
higher resistance to vincristine and paclitaxel.
When LY379196 was included in the medium there was a
clear difference in effect depending on the cell line
studied. For IMR-32, the least drug-resistant cell line, no
effect of LY379196 on the potency of the chemotherapeu-
tic drugs was observed. With 500 nM there was a suppres-
sion of the number of viable cells but this reflects the
inherent growth-suppressive effect of LY379196 (Figure
1) and was not due to an enhancement of the potency of
anticancer agents on IMR-32 cells.
For SH-SY5Y cells, concomitant exposure to 500 nM
LY379196 led to approximately a doubling of the potency
of doxorubicin, paclitaxel, and vincristine. The ED50 val-
ues were decreased from 9.3, 8.3 and 1.41 nM, respective-
ly, in the absence of LY379196 to 5.0, 4.3 and 0.57 nM
(column A in Table 1), respectively, in the presence of 500
nM LY379196. These values reflect the potency of the
chemotherapeutic drugs, since the growth-suppressing ef-
fect of LY379196 has been compensated for in the calcu-
lation. If the combined effect of 500 nM LY379196 and
the chemotherapeutic drugs is studied, the drug concen-
tration necessary to suppress the number of viable cells to
50% of the amount obtained in the absence of both
chemotherapeutic agent and LY379196 is further reduced
to 2.0 nM, 27 nM and 0.33 nM (column B in Table 1) for
doxorubicin, paclitaxel and vincristine, respectively. This
correlates to some degrees to the spectrum of drug resist-
ance of SH-SY5Y cells compared to IMR-32 cells since SH-
SY5Y cells are more resistant to both paclitaxel and vinc-
ristine. However, no effect was observed on the potency of
carboplatin, despite the fact that SH-SY5Y cells are less
sensitive to this compound.
The effect of LY379196 was most pronounced on SK-N-
BE(2) cells, the cell line with the lowest sensitivity to the
anticancer drugs. When 500 nM LY379196 was included
in the medium, there was an eight-fold decrease in the
ED50 value of vincristine (from 42 to 5.2 nM), approxi-
mately a three-fold decrease of the values for doxorubicin
(from 920 to 270 nM) and paclitaxel (from 117 to 40
nM), and also an enhancement of the etoposide effect
(column A in Table 1). These changes reflect an effect of
LY379196 on the potency of the chemotherapeutic com-
pounds since the inherent growth-inhibitory effect of
LY379196 was compensated for in the calculations. As for
SH-SY5Y cells, there was no effect of LY379196 on the
cytotoxic/growth suppressive effect of carboplatin (Figure
2, Table 1).
Figure 1
Suppression of neuroblastoma cell growth by 
LY379196. Neuroblastoma IMR-32 (A), SH-SY5Y (B), and 
SK-N-BE(2) (C) cells were grown for four (A and B) or three 
(C) days in regular growth medium supplemented with 
increasing concentrations of LY379196. Thereafter the 
number of viable cells was determined with an MTT assay. 
Data are expressed as percent of values obtained in the 
absence of LY379196 and are mean ± SEM (n = 9–18 from 3–
6 separate experiments).
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Figure 2
The effect of the combination of LY379196 and anticancer drugs on neuroblastoma cell growth. IMR-32, SH-
SY5Y, and SK-N-BE(2) cells were grown in medium supplemented with increasing concentrations of doxorubicin, etoposide, 
paclitaxel, vincristine, and carboplatin. Different amounts of LY379196 were also included in the medium yielding final concen-
trations of 0 (■ , black), 20 (● , red), 100 (▲ , green) or 500 (▼ , blue) nM. After three (SK-N-BE(2)) or four (IMR-32 and SH-
SY5Y) days in culture the amount of viable cells was analyzed with an MTT assay. The concentrations of the anticancer drugs 
are indicated on the x-axes as lg([drug]/1M). Data are expressed as percent of values obtained in the absence of drugs and are 
mean ± SEM (n = 8–9).
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If the potentiating effect on the chemotherapeutic drugs is
mediated via an inhibition of PKCβ isoforms, other
inhibitors of PKC would be expected to yield a similar ef-
fect. Therefore the effect of two PKC inhibitors,
GF109203X which inhibits all PKC isoforms and Gö6976
which only inhibits classical isoforms, on the growth-in-
hibiting effects of vincristine on SK-N-BE(2) cells was in-
vestigated (Figure 3, Table 2). This experiment
demonstrated that both these inhibitors increase the sen-
sitivity of SK-N-BE(2) cells to vincristine. When the
growth-suppressing effects of the inhibitors were compen-
sated for, we found that the ED50 of vincristine was rough-
ly halved in the presence of 500 nM of either inhibitor
(column A in Table 2). Gö6976 by itself also caused a sub-
stantial decrease of the amount viable cells.
The largest effect of LY379196 was observed for chemo-
therapeutic agents of the natural compound group and no
effect was seen together with carboplatin. Resistance to-
wards natural products has mostly been associated with a
multidrug resistance phenotype, which has been suggest-
ed to be due to an increased expression of proteins, which
pump out the compounds from the cells. To investigate
whether inhibition of PKCβ influences this mechanism of
resistance, the accumulation of [3H]vincristine was ana-
lyzed in the presence of increasing concentrations of PKC
inhibitors (Figure 4). All inhibitors used (LY379196,
GF109203X, and Gö6976) caused an enhancement of the
accumulation of [3H]vincristine. The specific PKCβ inhib-
itor, LY379196, was the most potent compound and the
concentrations which augmented the vincristine
accumulation reflected the concentrations that sensitized
the SK-N-BE(2) cells to vincristine.
Discussion
We have previously seen that inhibition of a PKCβ iso-
form, conceivably PKCβI, suppresses the proliferation of
the SK-N-BE(2) neuroblastoma cell line [5]. The data in
this study indicate that the proliferation supporting effect
of a PKCβ isoform may be general for neuroblastoma cells
since the growth of the two other cell lines tested also were
sensitive to the PKCβ inhibitor. When 300 nM LY379196
was included in the medium there were fewer cells after
four days in culture of all cell lines suggesting that the ef-
fect may be general for neuroblastoma cells.
The data in this study also demonstrate that the PKCβ in-
hibitor augments the effect of natural product chemother-
Table 1: Effects of LY379196 on ED50 values of chemotherapeutic drugs.
Doxorubicin Etoposide Paclitaxel Vincristine Carboplatin
IMR-32 (nM) (nM) (nM) (nM) (nM)
LY379196 ABABABABAB
0 nM 6.3 110 1.7 0.51 760
20 nM 5.5 5.3 101 118 1.6 1.7 0.47 0.57 780 740
100 nM 5.5 4.7 88 98 1.4 1.6 0.40 0.47 880 720
500 nM 6.1 2.8 103 78 1.6 1.0 0.37 0.30 880 380
SH-SY5Y (nM) (nM) (nM) (nM) (µM)
LY379196 ABABABABAB
0 nM 9.3 109 8.3 1.41 1.9
20 nM 8.2 9.8 93 114 7.3 8.0 1.20 1.45 2.2 2.3
100 nM 7.2 6.7 74 81 4.8 4.3 0.82 0.89 2.1 1.8
500 nM 5.0 2.0 75 55 4.3 2.7 0.57 0.33 2.0 0.7
SK-N-BE(2) (nM) (µM) (nM) (nM) (µM)
LY379196 ABABABABAB
0 nM 920 7.2 117 42 >100
20 nM 650 690 6.4 6.6 108 109 32 33 >100 >100
100 nM 450 380 5.3 4.8 105 94 21 21 >100 >100
500 nM 270 160 3.9 2.8 40 27 5.2 3.9 >100 >100
This table shows the concentrations (ED50) of the chemotherapeutic drugs, in the presence of different LY379196 concentrations, needed to sup-
press the number of viable cells after three (SK-N-BE(2)) or four (IMR-32 and SH-SY5Y) days in culture to 50% of the amount obtained in the 
absence of the drug. The data used for calculations are obtained from Figure 2. Values are geometric mean of three separate experiments with trip-
licate measurements. The ED50 values were calculated using the amount of viable cells in the absence of chemotherapeutic drug but in the presence 
of LY379196 as 100% (values in A columns) or the amount of viable cells in the absence of anticancer drug and LY379196 (values in B columns). 
Thus, values in column A reflect the potency of the chemotherapeutic drug since the inherent growth-suppressing effect of LY379196 has been 
eliminated in the calculations, whereas values in column B reflect the combined growth-suppressing effect of LY379196 and chemotherapeutic drug. 
For carboplatin treatment of SK-N-BE(2) cells a reduction in viable cell amount by 50% was not obtained within the concentration range used.BMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/10
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Figure 3
The effect of the combination of PKC inhibitors and vincristine on SK-N-BE(2) cell growth. SK-N-BE(2) cells were 
grown in medium supplemented with increasing concentrations of vincristine. Different amounts of GF109203X (A) or 
Gö6976 (B) were also included in the medium yielding final concentrations of 0 (■ , black), 20 (● , red), 100 (▲ , green) or 500 
(▼ , blue) nM. After three days in culture the amount of viable cells was analyzed with an MTT assay. The concentration of vin-
cristine is indicated on the x-axes as lg([drug]/1M). Data are expressed as percent of values obtained in the absence of drugs 
and are mean ± SEM (n = 8–9).
Table 2: Effects of GF109203X and Gö6976 on ED50 values of vincristine.
GF109203X Gö6976
(nM) (nM)
PKC inhibitor ABAB
0 nM 41 49
20 nM 30 35 35 35
100 nM 26 26 39 31
500 nM 28 18 24 NA
This table shows the concentrations (ED50) of vincristine, in the presence of different concentrations of GF109203X or Gö6976, needed to sup-
press the number of viable SK-N-BE(2) cells after three days in culture to 50% of the amount obtained in the absence of the drug. The data used for 
calculations are obtained from Figure 3. Values are geometric mean of three separate experiment with triplicate measurements. The ED50 values 
were calculated using the amount of viable cells in the absence of vincristine but in the presence of PKC inhibitor as 100% (values in A columns) or 
the amount of viable cells in the absence of vincristine and PKC inhibitor (values in B columns). Thus, values in column A reflect the potency of vin-
cristine since the inherent growth-suppressing effect of the PKC inhibitors has been eliminated in the calculations, whereas values in column B 
reflect the combined growth-suppressing effect of PKC inhibitor and vincristine.NA – not available because culture in the presence of 500 nM 
Gö6976 reduced the number of cells to less than 50% of the number obtained in the absence of the compound.
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apeutic agents on multidrug-resistant neuroblastoma
cells. In contrast to the effect on proliferation, which in-
fluenced all cell lines, the augmentation of the anticancer
drugs was related to the grade of drug resistance of the cell
line. It is therefore conceivable that LY379196 interferes
with mechanisms that confer drug resistance to neurob-
lastoma cells, although it can not be excluded that other
factors than the degree of drug resistance explain the dif-
ference in sensitivity to LY379196 in the presence of
chemotherapeutic drugs.
The acquisition of multidrug resistance upon treatment
with anti-cancer drugs is a common phenomenon for
neuroblastomas [2]. This is a major reason for the high
frequency of fatal outcome of the disease. Drug resistance
of cancer cells has been suggested to be caused by in-
creased expression of proteins of the ATP-binding cassette
transporter family such as the MDR1 protein product P-
glycoprotein and MRP. High expression of MDR1 in neu-
roblastomas was shown to be related to previous chemo-
therapeutic treatment [8], to drug resistance [9] and to
bad prognosis in a subset of cases [10]. However, it was
also shown to correlate inversely to MYCN amplification
Figure 4
PKC inhibitors augment the accumulation of [3H]vincristine in SK-N-BE(2) cells. Different concentrations of 
LY379196, GF109203X and Gö6976 were added to SK-N-BE(2) cells 15 min prior to a 2 h incubation with [3H]vincristine. The 
amount of the radioactivity that had accumulated in the cells was thereafter measured. Data are expressed as percent of 
[3H]vincristine that had accumulated in cells that had not been exposed to inhibitor and are mean ± SEM of 8 determinations.
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[11] and to good prognosis [12]. High expression of MRP
has been reported to be prognostic for pour outcome [13]
although other studies have not found this connection
[14,15]. The expression of MRP is positively influenced by
MYCN [16], which is frequently amplified in neuroblast-
omas with pour outcome. Thus, the specific role of the
MDR1 and MRP genes in the acquisition of drug-resist-
ance of neuroblastomas has not yet been settled.
Another study has instead indicated a role for mutation
and inactivation of the TP53 tumor suppressor gene in
drug resistant neuroblastomas [17,18]. Furthermore a re-
cent report has shown that chromosome reassortments
can lead to drug resistance in cells that lack the MDR1 and
MRP1 genes that are thought to confer multidrug resist-
ance [19].
The data in this study demonstrate a correlation between
the potentiation of cytotoxic/growth suppressing effects
of natural compound anti-cancer drugs and an enhance-
ment of [3H]vincristine accumulation by PKC inhibitors
in neuroblastoma cells. This suggests that the drug resist-
ance of the SK-N-BE(2) cells is at least partially mediated
by increased elimination of natural products by efflux
pumps such as products of the MDR1 and MRP genes.
This is supported by studies which have shown that agents
that interfere with these pumps sensitizes drug resistant
neuroblastoma cells to chemotherapeutic agents of the
natural compound class [20,21]. Furthermore, LY379196
did not augment the effect of carboplatin, which is not a
substrate for pumps of the P-glycoprotein family.
PKC activity was initially thought to support the activity of
P-glycoprotein since it was shown to be a PKC substrate
[22–24] and PKC inhibitors were reported to suppress the
activity of the protein [22,24,25]. However, later studies
demonstrated that phosphorylation of P-glycoprotein did
not influence its function [26,27]. It has also been shown
that GF109203X directly influences the activity of P-glyc-
oprotein by competing with other substrates [28] and a
similar mechanism of action has also been suggested for
the effect of GF109203X on MRP [29] and for the reversal
of drug resistance by the PKC inhibitor Ro 32-2241 [30].
The effect of LY379196 may therefore be due to a compe-
tition with the anticancer drugs for P-glycoprotein or oth-
er members of this family.
However, there are other reports demonstrating attenuat-
ing effects of PKC inhibitors on drug resistance that do not
involve P-glycoprotein. Safingol and a myristoylated PKC
pseudosubstrate peptide have been shown to inhibit PKC
and potentiate drug accumulation independently of ef-
fects on P-glycoprotein [31–33]. The data in this study in-
dicate that a PKCβ isoform could be a relevant isoform to
inhibit in order to attenuate PKC-supported drug resist-
ance. It is notable that the inhibitor with highest specifici-
ty for PKCβ also had the most profound effect on the
cytotoxicity of vincristine. The smaller effect of the other
inhibitors could for instance be due to inhibition of pro-
apoptotic PKC isoforms such as PKCδ, which has been
shown to be important for apoptosis in several cell types
[34–38]. It should be noted that Gö6976 alone causes a
substantial decrease of viable neuroblastoma cells, which
may imply toxic effects attendant to the lack of isoform
specificity. This could mask a potentiating effect on the
cytotoxicity of vincristine and also preclude the use of
Gö6976 at effective concentrations.
Conclusions
this study raises the potential to use PKCβ isoforms as tar-
gets to both partially suppress proliferation and to attenu-
ate the multidrug resistance of neuroblastoma cells.
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